Role of therapeutic drug monitoring in pulmonary infections: Use and potential for expanded use of dried blood spot samples

Bioanalysis

Volumn 7, Issue 4, 2015, Pages 481-495

  Hofman, Susan ^a   Bolhuis, Mathieu S ^a   Koster, Remco A ^a   Akkerman, Onno W ^a   Van Assen, Sander ^a   Stove, Christophe ^b   Alffenaar, Jan Willem C ^a  

^a UNIVERSITY MEDICAL CENTER GRONINGEN   (Netherlands)

^b GHENT UNIVERSITY   (Belgium)

Author keywords

[No Author keywords available]

Indexed keywords

AMINOGLYCOSIDE ANTIBIOTIC AGENT; ANTIFUNGAL AGENT; ANTIVIRUS AGENT; BEDAQUILINE; BETA LACTAM ANTIBIOTIC; COTRIMOXAZOLE; DELAMANID; GENTAMICIN; LINCOSAMIDE; LINEZOLID; MACROLIDE; OXAZOLIDINONE DERIVATIVE; POLYPEPTIDE ANTIBIOTIC AGENT; POSACONAZOLE; QUINOLINE DERIVED ANTIINFECTIVE AGENT; RIFAMYCIN DERIVATIVE; TETRACYCLINE DERIVATIVE; TUBERCULOSTATIC AGENT; VORICONAZOLE;

ANTIBIOTIC THERAPY; ANTIMICROBIAL THERAPY; ANTIVIRAL THERAPY; DRIED BLOOD SPOT TESTING; DRUG MONITORING; FEASIBILITY STUDY; HUMAN; LUNG INFECTION; NONHUMAN; REVIEW; ANIMAL; BLOOD; DRUG EFFECTS; LUNG; PROCEDURES; RESPIRATORY TRACT INFECTIONS;

ANIMALS; DRIED BLOOD SPOT TESTING; DRUG MONITORING; HUMANS; LUNG; RESPIRATORY TRACT INFECTIONS;

EID: 84924415769     PISSN: 17576180     EISSN: 17576199     Source Type: Journal    
DOI: 10.4155/bio.14.318     Document Type: Review

References (123)

1. Yu X, Han F, Wu J et al. Nocardia infection in kidney transplant recipients: case report and analysis of 66 published cases. Transpl. Infect. Dis. 13 (4), 385-391 (2011).
2. Miszkiel KA, Wells AU, Rubens MB, Cole PJ, Hansell DM. Effects of airway infection by Pseudomonas aeruginosa: a computed tomographic study. Thorax 52 (3), 260-264 (1997).
3. Wark PA, Tooze M, Powell H, Parsons K. Viral and bacterial infection in acute asthma and chronic obstructive pulmonary disease increases the risk of readmission. Respirology 18 (6), 996-1002 (2013).
4. van Westreenen M, Tiddens HA. New antimicrobial strategies in cystic fibrosis. Paediatr. Drugs 12 (6), 343-352 (2010).
5. Chai LY, Hsu LY. Recent advances in invasive pulmonary aspergillosis. Curr. Opin. Pulm. Med. 17 (3), 160-166 (2011).
6. Barberan J, Sanz F, Hernandez JL et al. Clinical features of invasive pulmonary aspergillosis vs. colonization in COPD patients distributed by gold stage. J. Infect. 65 (5), 447-452 (2012).
7. Lim WS, van der Eerden MM, Laing R et al. Defining community acquired pneumonia severity on presentation to hospital: an international derivation and validation study. Thorax 58 (5), 377-382 (2003).
8. Fine MJ, Auble TE, Yealy DM et al. A prediction rule to identify low-risk patients with community-acquired pneumonia. N. Engl. J. Med. 336 (4), 243-250 (1997).
9. Angrill J, Agusti C, de Celis R et al. Bacterial colonisation in patients with bronchiectasis: microbiological pattern and risk factors. Thorax 57 (1), 15-19 (2002).
10. Domenech A, Puig C, Marti S et al. Infectious etiology of acute exacerbations in severe COPD patients. J. Infect. 67 (6), 516-523 (2013).
11. Hoefsloot W, van Ingen J, Magis-Escurra C et al. Prevalence of nontuberculous mycobacteria in COPD patients with exacerbations. J. Infect. 66 (6), 542-545 (2013).
12. van Ingen J, Ferro BE, Hoefsloot W, Boeree MJ, van Soolingen D. Drug treatment of pulmonary nontuberculous mycobacterial disease in HIV-negative patients: the evidence. Expert Rev. Anti Infect. Ther. 11 (10), 1065-1077 (2013).
13. Knoll BM. Update on nontuberculous mycobacterial infections in solid organ and hematopoietic stem cell transplant recipients. Curr. Infect. Dis. Rep. 16 (9), 421 (2014).
14. De Waele JJ, Lipman J, Akova M et al. Risk factors for target non-attainment during empirical treatment with betalactam antibiotics in critically ill patients. Intensive Care Med. 40 (9), 1340-1351 (2014).
15. Bruggemann RJ, Alffenaar JW, Blijlevens NM et al. Clinical relevance of the pharmacokinetic interactions of azole antifungal drugs with other coadministered agents. Clin. Infect. Dis. 48 (10), 1441-1458 (2009).
16. Mouton JW, Dudley MN, Cars O, Derendorf H, Drusano GL. Standardization of pharmacokinetic/pharmacodynamic (PK/PD) terminology for anti-infective drugs: an update. J. Antimicrob. Chemother. 55 (5), 601-607 (2005).
17. Martinez MN, Papich MG, Drusano GL. Dosing regimen matters: the importance of early intervention and rapid attainment of the pharmacokinetic/pharmacodynamic target. Antimicrob. Agents Chemother. 56 (6), 2795-2805 (2012).
18. Vu DH, Alffenaar JW, Edelbroek PM, Brouwers JR, Uges DR. Dried blood spots: a new tool for tuberculosis treatment optimization. Curr. Pharm. Des. 17 (27), 2931-2939 (2011).
19. Ter Heine R, Mulder JW, van Gorp EC, Wagenaar JF, Beijnen JH, Huitema AD. Clinical evaluation of the determination of plasma concentrations of darunavir, etravirine, raltegravir and ritonavir in dried blood spot samples. Bioanalysis 3 (10), 1093-1097 (2011).
20. Taneja I, Erukala M, Raju KS, Singh SP, Wahajuddin, . Dried blood spots in bioanalysis of antimalarials: relevance and challenges in quantitative assessment of antimalarial drugs. Bioanalysis 5 (17), 2171-2186 (2013).
21. Edelbroek PM, van der Heijden J, Stolk LM. Dried blood spot methods in therapeutic drug monitoring: methods, assays, and pitfalls. Ther. Drug Monit. 31 (3), 327-336 (2009).
22. De Kesel PM, Capiau S, Stove VV, Lambert WE, Stove CP. Potassium-based algorithm allows correction for the hematocrit bias in quantitative analysis of caffeine and its major metabolite in dried blood spots. Anal. Bioanal Chem. 406 (26), 6749-6755 (2014).
23. Johansson I, Ingelman-Sundberg M. Genetic polymorphism and toxicology-with emphasis on cytochrome p450. Toxicol. Sci. 120 (1), 1-13 (2011).
24. Mouton JW, Touzw DJ, Horrevorts AM, Vinks AA. Comparative pharmacokinetics of the carbapenems: clinical implications. Clin. Pharmacokinet. 39 (3), 185-201 (2000).
25. Munar MY, Singh H. Drug dosing adjustments in patients with chronic kidney disease. Am. Fam. Physician 75 (10), 1487-1496 (2007).
26. Thijssen HH, Wolters J. The metabolic disposition of flucloxacillin in patients with impaired kidney function. Eur. J. Clin. Pharmacol. 22 (5), 429-434 (1982).
27. Patel IH, Sugihara JG, Weinfeld RE, Wong EG, Siemsen AW, Berman SJ. Ceftriaxone pharmacokinetics in patients with various degrees of renal impairment. Antimicrob. Agents Chemother. 25 (4), 438-442 (1984).
28. Zhanel GG, Wiebe R, Dilay L et al. Comparative review of the carbapenems. Drugs 67 (7), 1027-1052 (2007).
29. Mistry GC, Majumdar AK, Swan S et al. Pharmacokinetics of ertapenem in patients with varying degrees of renal insufficiency and in patients on hemodialysis. J. Clin. Pharmacol. 46 (10), 1128-1138 (2006).
30. Trotman RL, Williamson JC, Shoemaker DM, Salzer WL. Antibiotic dosing in critically ill adult patients receiving continuous renal replacement therapy. Clin. Infect. Dis. 41 (8), 1159-1166 (2005).
31. Leise MD, Poterucha JJ, Talwalkar JA. Drug-induced liver injury. Mayo Clin. Proc. 89 (1), 95-106 (2014).
32. Pea F, Furlanut M. Pharmacokinetic aspects of treating infections in the intensive care unit: focus on drug interactions. Clin. Pharmacokinet. 40 (11), 833-868 (2001).
33. Wong G, Brinkman A, Benefield RJ et al. An international, multicentre survey of beta-lactam antibiotic therapeutic drug monitoring practice in intensive care units. J. Antimicrob. Chemother. 69 (5), 1416-1423 (2014).
34. Welling PG, Shaw WR, Uman SJ, Tse FL, Craig WA. Pharmacokinetics of minocycline in renal failure. Antimicrob. Agents Chemother. 8 (5), 532-537 (1975).
35. Neuvonen PJ, Gothoni G, Hackman R, Bjorksten K. Interference of iron with the absorption of tetracyclines in man. Br. Med. J. 4 (5734), 532-534 (1970).
36. Zhou SF, Xue CC, Yu XQ, Li C, Wang G. Clinically important drug interactions potentially involving mechanism-based inhibition of cytochrome P450 3A4 and the role of therapeutic drug monitoring. Ther. Drug Monit. 29 (6), 687-710 (2007).
37. Leroy B, Uhart M, Maire P, Bourguignon L. Evaluation of fluoroquinolone reduced dosage regimens in elderly patients by using pharmacokinetic modelling and Monte Carlo simulations. J. Antimicrob. Chemother. 67 (9), 2207-2212 (2012).
38. Aminimanizani A, Beringer P, Jelliffe R. Comparative pharmacokinetics and pharmacodynamics of the newer fluoroquinolone antibacterials. Clin. Pharmacokinet. 40 (3), 169-187 (2001).
39. Albertson TE, Dean NC, El Solh AA, Gotfried MH, Kaplan C, Niederman MS. Fluoroquinolones in the management of community-acquired pneumonia. Int. J. Clin. Pract. 64 (3), 378-388 (2010).
40. Barth J, Jager D, Mundkowski R, Drewelow B, Welte T, Burkhardt O. Single- and multiple-dose pharmacokinetics of intravenous moxifloxacin in patients with severe hepatic impairment. J. Antimicrob. Chemother. 62 (3), 575-578 (2008).
41. Stockmann C, Sherwin CM, Zobell JT et al. Optimization of anti-pseudomonal antibiotics for cystic fibrosis pulmonary exacerbations: III. fluoroquinolones. Pediatr. Pulmonol. 48 (3), 211-220 (2013).
42. Pranger AD, Alffenaar JW, Aarnoutse RE. Fluoroquinolones, the cornerstone of treatment of drug-resistant tuberculosis: a pharmacokinetic and pharmacodynamic approach. Curr. Pharm. Des. 17 (27), 2900-2930 (2011).
43. Begg EJ, Barclay ML, Kirkpatrick CM. The therapeutic monitoring of antimicrobial agents. Br. J. Clin. Pharmacol. 52 (Suppl. 1), S35-S43 (2001).
44. Avent ML, Rogers BA, Cheng AC, Paterson DL. Current use of aminoglycosides: indications, pharmacokinetics and monitoring for toxicity. Intern. Med. J. 41 (6), 441-449 (2011).
45. Arbex MA, Varella Mde C, Siqueira HR, Mello FA. Antituberculosis drugs: drug interactions, adverse effects, and use in special situations. Part 2: second line drugs. J. Bras. Pneumol. 36 (5), 641-656 (2010).
46. Lange C, Abubakar I, Alffenaar JW et al. Management of patients with multidrug-resistant/extensively drug-resistant tuberculosis in Europe: a TBNET consensus statement. Eur. Respir. J. (2014).
47. Nahata M. Drug interactions with azithromycin and the macrolides: an overview. J. Antimicrob. Chemother. 37 (Suppl. C), 133-142 (1996).
48. Gilljam M, Berning SE, Peloquin CA, Strandvik B, Larsson LO. Therapeutic drug monitoring in patients with cystic fibrosis and mycobacterial disease. Eur. Respir. J. 14 (2), 347-351 (1999).
49. Arbex MA, Varella Mde C, Siqueira HR, Mello FA. Antituberculosis drugs: drug interactions, adverse effects, and use in special situations. Part 1: first-line drugs. J. Bras. Pneumol. 36 (5), 626-640 (2010).
50. Yew WW. Clinically significant interactions with drugs used in the treatment of tuberculosis. Drug Saf. 25 (2), 111-133 (2002).
51. Alsultan A, Peloquin CA. Therapeutic drug monitoring in the treatment of tuberculosis: an update. Drugs 74 (8), 839-854 (2014).
52. Domart Y, Pierre C, Clair B, Garaud JJ, Regnier B, Gibert C. Pharmacokinetics of teicoplanin in critically ill patients with various degrees of renal impairment. Antimicrob. Agents Chemother. 31 (10), 1600-1604 (1987).
53. Wilson AP. Clinical pharmacokinetics of teicoplanin. Clin. Pharmacokinet. 39 (3), 167-183 (2000).
54. Walker CB. Selected antimicrobial agents: mechanisms of action, side effects and drug interactions. Periodontol. 2000 10, 12-28 (1996).
55. Peloquin CA. Therapeutic drug monitoring in the treatment of tuberculosis. Drugs 62 (15), 2169-2183 (2002).
56. Baciewicz AM, Chrisman CR, Finch CK, Self TH. Update on rifampin, rifabutin, and rifapentine drug interactions. Curr. Med. Res. Opin. 29 (1), 1-12 (2013).
57. Brown GR. Cotrimoxazole - optimal dosing in the critically ill. Ann. Intensive Care 4, 13 (2014).
58. Ho JM, Juurlink DN. Considerations when prescribing trimethoprim-sulfamethoxazole. CMAJ 183 (16), 1851-1858 (2011).
59. van Heeswijk RP, Dannemann B, Hoetelmans RM. Bedaquiline: a review of human pharmacokinetics and drug-drug interactions. J. Antimicrob. Chemother. 69 (9), 2310-2318 (2014).
60. Centers for Disease Control and Prevention. Provisional CDC guidelines for the use and safety monitoring of bedaquiline fumarate (Sirturo) for the treatment of multidrug-resistant tuberculosis. MMWR Recomm. Rep. 62 (RR-09), 1-12 (2013).
61. Czock D, Scholle C, Rasche FM, Schaarschmidt D, Keller F. Pharmacokinetics of valganciclovir and ganciclovir in renal impairment. Clin. Pharmacol. Ther. 72 (2), 142-150 (2002).
62. Jacobsen T, Sifontis N. Drug interactions and toxicities associated with the antiviral management of cytomegalovirus infection. Am. J. Health. Syst. Pharm. 67 (17), 1417-1425 (2010).
63. Brody SR, Humphreys MH, Gambertoglio JG, Schoenfeld P, Cundy KC, Aweeka FT. Pharmacokinetics of cidofovir in renal insufficiency and in continuous ambulatory peritoneal dialysis or high-flux hemodialysis. Clin. Pharmacol. Ther. 65 (1), 21-28 (1999).
64. Smith JR, Rayner CR, Donner B, Wollenhaupt M, Klumpp K, Dutkowski R. Oseltamivir in seasonal, pandemic, and avian influenza: a comprehensive review of 10-years clinical experience. Adv. Ther. 28 (11), 927-959 (2011).
65. Weller S, Jones LS, Lou Y, Peppercorn A, Ng-Cashin J. Pharmacokinetics of zanamivir following intravenous administration to subjects with and without renal impairment. Antimicrob. Agents Chemother. 57 (7), 2967- 2971 (2013).
66. Blum MR, Liao SH, de Miranda P. Overview of acyclovir pharmacokinetic disposition in adults and children. Am. J. Med. 73 (1A), 186-192 (1982).
67. Perrottet N, Decosterd LA, Meylan P, Pascual M, Biollaz J, Buclin T. Valganciclovir in adult solid organ transplant recipients: pharmacokinetic and pharmacodynamic characteristics and clinical interpretation of plasma concentration measurements. Clin. Pharmacokinet. 48 (6), 399-418 (2009).
68. Stanke-Labesque F, Loustaud-Ratti V, Babany G, Gagnieu MC, Marquet P, French Ribavirin Group OPTIRIB. Ribavirin therapeutic drug monitoring: why, when and how? Fundam. Clin. Pharmacol. 24 (4), 401-406 (2010).
69. Snijdewind IJ, van Kampen JJ, Fraaij PL, van der Ende ME, Osterhaus AD, Gruters RA. Current and future applications of dried blood spots in viral disease management. Antiviral Res. 93 (3), 309-321 (2012).
70. Hope WW, Billaud EM, Lestner J, Denning DW. Therapeutic drug monitoring for triazoles. Curr. Opin. Infect. Dis. 21 (6), 580-586 (2008).
71. Kuo IF, Ensom MH. Role of therapeutic drug monitoring of voriconazole in the treatment of invasive fungal infections. Can. J. Hosp. Pharm. 62 (6), 469-482 (2009).
72. Gubbins PO. Triazole antifungal agents drug-drug interactions involving hepatic cytochrome P450. Expert Opin. Drug Metab. Toxicol. 7 (11), 1411-1429 (2011).
73. Gubbins PO, Heldenbrand S. Clinically relevant drug interactions of current antifungal agents. Mycoses 53 (2), 95-113 (2010).
74. Summers KK, Hardin TC, Gore SJ, Graybill JR. Therapeutic drug monitoring of systemic antifungal therapy. J. Antimicrob. Chemother. 40 (6), 753-764 (1997).
75. Howard SJ, Felton TW, Gomez-Lopez A, Hope WW. Posaconazole: the case for therapeutic drug monitoring. Ther. Drug Monit. 34 (1), 72-76 (2012).
76. Moen MD, Lyseng-Williamson KA, Scott LJ. Liposomal amphotericin B: a review of its use as empirical therapy in febrile neutropenia and in the treatment of invasive fungal infections. Drugs 69 (3), 361-392 (2009).
77. Chen SC, Slavin MA, Sorrell TC. Echinocandin antifungal drugs in fungal infections: a comparison. Drugs 71 (1), 11-41 (2011).
78. van Wanrooy MJ, Santoe RN, van der Elst KC et al. Simultaneous quantification of anidulafungin and caspofungin in plasma by an accurate and simple liquid chromatography tandem mass-spectrometric method. Ther. Drug Monit. 35 (6), 778-784 (2013).
79. Kotloff RM, Ahya VN, Crawford SW. Pulmonary complications of solid organ and hematopoietic stem cell transplantation. Am. J. Respir. Crit. Care Med. 170 (1), 22-48 (2004).
80. Bijleveld Y, de Haan T, Toersche J et al. A simple quantitative method analysing amikacin, gentamicin, and vancomycin levels in human newborn plasma using ion-pair liquid chromatography/tandem mass spectrometry and its applicability to a clinical study. J. Chromatogr. B. Analyt Technol. Biomed. Life Sci. 951-952, 110-118 (2014).
81. Long YH, Hernandez M, Kaale E et al. Determination of kanamycin in serum by solid-phase extraction, pre-capillary derivatization and capillary electrophoresis. J. Chromatogr. B. Analyt Technol. Biomed. Life. Sci 784 (2), 255-264 (2003).
82. Dijkstra JA, Sturkenboom MG, Hateren K, Koster RA, Greijdanus B, Alffenaar JW. Quantification of amikacin and kanamycin in serum using a simple and validated LC-MS/ MS method. Bioanalysis 6 (16), 2125-2133 (2014).
83. Zhu M, Burman WJ, Jaresko GS, Berning SE, Jelliffe RW, Peloquin CA. Population pharmacokinetics of intravenous and intramuscular streptomycin in patients with tuberculosis. Pharmacotherapy 21 (9), 1037-1045 (2001).
84. Zhou Z, Wu X, Wei Q et al. Development and validation of a hydrophilic interaction liquid chromatography-tandem mass spectrometry method for the simultaneous determination of five first-line antituberculosis drugs in plasma. Anal. Bioanal. Chem. 405 (19), 6323-6335 (2013).
85. Sanchez-Alcaraz A, Vargas A, Quintana MB et al. Therapeutic drug monitoring of tobramycin: once-daily versus twice-daily dosage schedules. J. Clin. Pharm. Ther. 23 (5), 367-373 (1998).
86. Attema-de Jonge ME, Bekkers JM, Oudemans-van Straaten HM, Sparidans RW, Franssen EJ. Simple and sensitive method for quantification of low tobramycin concentrations in human plasma using HPLC-MS/MS. J. Chromatogr. B. Analyt. Technol. Biomed. Life Sci. 862 (1-2), 257-262 (2008).
87. Cirillo I, Vaccaro N, Turner K, Solanki B, Natarajan J, Redman R. Pharmacokinetics, safety, and tolerability of doripenem after 0.5-, 1-, and 4-hour infusions in healthy volunteers. J. Clin. Pharmacol. 49 (7), 798-806 (2009).
88. Ohmori T, Suzuki A, Niwa T et al. Simultaneous determination of eight beta-lactam antibiotics in human serum by liquid chromatography-tandem mass spectrometry. J. Chromatogr. B. Analyt Technol. Biomed. Life Sci. 879 (15- 16), 1038-1042 (2011).
89. Sakka SG, Glauner AK, Bulitta JB et al. Population pharmacokinetics and pharmacodynamics of continuous versus short-term infusion of imipenem-cilastatin in critically ill patients in a randomized, controlled trial. Antimicrob. Agents Chemother. 51 (9), 3304-3310 (2007).
90. Leroy A, Fillastre JP, Borsa-Lebas F, Etienne I, Humbert G. Pharmacokinetics of meropenem (ICI 194, 660) and its metabolite (ICI 213, 689) in healthy subjects and in patients with renal impairment. Antimicrob. Agents Chemother. 36 (12), 2794-2798 (1992).
91. Sime FB, Roberts MS, Roberts JA, Robertson TA. Simultaneous determination of seven beta-lactam antibiotics in human plasma for therapeutic drug monitoring and pharmacokinetic studies. J. Chromatogr. B. Analyt Technol. Biomed. Life Sci. 960, 134-144 (2014).
92. Smyth RD, Pfeffer M, Glick A, Van Harken DR, Hottendorf GH. Clinical pharmacokinetics and safety of high doses of ceforanide (BL-S786R) and cefazolin. Antimicrob. Agents Chemother. 16 (5), 615-621 (1979).
93. Ings RM, Fillastre JP, Godin M, Leroy A, Humbert G. The pharmacokinetics of cefotaxime and its metabolites in subjects with normal and impaired renal function. Rev. Infect. Dis. 4 (Suppl.), S379-S391 (1982).
94. Szultka M, Krzeminski R, Jackowski M, Buszewski B. Simultaneous determination of selected chemotherapeutics in human whole blood by molecularly imprinted polymers coated solid phase microextraction fibers and liquid chromatography-tandem mass spectrometry. J. Chromatogr. B. Analyt Technol. Biomed. Life Sci. 940, 66-76 (2013).
95. Ljungberg B, Nilsson-Ehle I. Comparative pharmacokinetics of ceftazidime in young, healthy and elderly, acutely ill males. Eur. J. Clin. Pharmacol. 34 (2), 179-186 (1988).
96. Harb G, Lebel F, Battikha J, Thackara JW. Safety and pharmacokinetics of subcutaneous ceftriaxone administered with or without recombinant human hyaluronidase (rHuPH20) versus intravenous ceftriaxone administration in adult volunteers. Curr. Med. Res. Opin. 26 (2), 279-288 (2010).
97. Foord RD. Cefuroxime: human pharmacokinetics. Antimicrob. Agents Chemother. 9 (5), 741-747 (1976).
98. Partani P, Gurule S, Khuroo A, Monif T, Bhardwaj S. Liquid chromatography/electrospray tandem mass spectrometry method for the determination of cefuroxime in human plasma: application to a pharmacokinetic study. J. Chromatogr. B. Analyt Technol. Biomed. Life Sci. 878 (3-4), 428-434 (2010).
99. Swabb EA, Singhvi SM, Leitz MA, Frantz M, Sugerman A. Metabolism and pharmacokinetics of aztreonam in healthy subjects. Antimicrob. Agents Chemother. 24 (3), 394-400 (1983).
100. Burkhardt O, Borner K, von der Hoh N et al. Single- and multiple-dose pharmacokinetics of linezolid and co-amoxiclav in healthy human volunteers. J. Antimicrob. Chemother. 50 (5), 707-712 (2002).
101. Rumble RH, Roberts MS, Scott AR. The effects of posture on the pharmacokinetics of intramuscular benzylpenicillin. Eur. J. Clin. Pharmacol. 33 (6), 629-635 (1988).
102. Landersdorfer CB, Kirkpatrick CM, Kinzig-Schippers M et al. Population pharmacokinetics at two dose levels and pharmacodynamic profiling of flucloxacillin. Antimicrob. Agents Chemother. 51 (9), 3290-3297 (2007).
103. Lubasch A, Keller I, Borner K, Koeppe P, Lode H. Comparative pharmacokinetics of ciprofloxacin, gatifloxacin, grepafloxacin, levofloxacin, trovafloxacin, and moxifloxacin after single oral administration in healthy volunteers. Antimicrob. Agents Chemother. 44 (10), 2600-2603 (2000).
104. Chow AT, Fowler C, Williams RR, Morgan N, Kaminski S, Natarajan J. Safety and pharmacokinetics of multiple 750-milligram doses of intravenous levofloxacin in healthy volunteers. Antimicrob. Agents Chemother. 45 (7), 2122-2125 (2001).
105. Jourdil JF, Tonini J, Stanke-Labesque F. Simultaneous quantitation of azole antifungals, antibiotics, imatinib, and raltegravir in human plasma by two-dimensional high-performance liquid chromatography-tandem mass spectrometry. J. Chromatogr. B. Analyt Technol. Biomed. Life Sci. 919-920, 1-9 (2013).
106. Farinotti R, Trouvin JH, Bocquet V, Vermerie N, Carbon C. Pharmacokinetics of ofloxacin after single and multiple intravenous infusions in healthy subjects. Antimicrob. Agents Chemother. 32 (10), 1590-1592 (1988).
107. Meredith SA, Smith PJ, Norman J, Wiesner L. An LC-MS/MS method for the determination of ofloxacin in 20 mul human plasma. J. Pharm. Biomed. Anal. 58, 177-181 (2012).
108. Carver PL, Nightingale CH, Quintiliani R, Sweeney K, Stevens RC, Maderazo E. Pharmacokinetics of single- and multiple-dose teicoplanin in healthy volunteers. Antimicrob. Agents Chemother. 33 (1), 82-86 (1989).
109. Tsai IL, Sun HY, Chen GY, Lin SW, Kuo CH. Simultaneous quantification of antimicrobial agents for multidrug-resistant bacterial infections in human plasma by ultra-high-pressure liquid chromatography-tandem mass spectrometry. Talanta 116, 593-603 (2013).
110. Patel DS, Sharma N, Patel MC, Patel BN, Shrivastav PS, Sanyal M. Development and validation of a selective and sensitive LC-MS/MS method for determination of cycloserine in human plasma: application to bioequivalence study. J. Chromatogr. B. Analyt Technol. Biomed. Life Sci. 879 (23), 2265-2273 (2011).
111. Polagani SR, Pilli NR, Maddela R, Gajula R, Gandu V. A rapid and sensitive liquid chromatography-tandem mass spectrometric assay for cycloserine in 50muL of human plasma: Its pharmacokinetic application. J. Pharm. Biomed. Anal. 76, 21-27 (2013).
112. FDA 2. Anti-Infective Drugs Advisory Committee Meeting Briefing Document TMC207 (bedaquiline) Treatment of Patients with MDR-TB. NDA 204-384 (2012).
113. Breda M, Benedetti MS, Bani M et al. Effect of rifabutin on ethambutol pharmacokinetics in healthy volunteers. Pharmacol. Res. 40 (4), 351-356 (1999).
114. Gler MT, Skripconoka V, Sanchez-Garavito E et al. Delamanid for multidrug-resistant pulmonary tuberculosis. N. Engl. J. Med. 366 (23), 2151-2160 (2012).
115. Choudhary N, Khajuria V, Gillani ZH, Tandon VR, Arora E. Effect of Carum carvi, a herbal bioenhancer on pharmacokinetics of antitubercular drugs: a study in healthy human volunteers. Perspect. Clin. Res. 5 (2), 80-84 (2014).
116. Spicehandler J, Pollock AA, Simberkoff MS, Rahal JJ Jr. Intravenous pharmacokinetics and in vitro bactericidal activity of trimethoprim-sulfamethoxazole. Rev. Infect. Dis. 4 (2), 562-565 (1982).
117. Bedor DC, Goncalves TM, Ferreira ML et al. Simultaneous determination of sulfamethoxazole and trimethoprim in biological fluids for high-throughput analysis: comparison of HPLC with ultraviolet and tandem mass spectrometric detection. J. Chromatogr. B. Analyt Technol. Biomed. Life Sci. 863 (1), 46-54 (2008).
118. Stone JA, Holland SD, Wickersham PJ et al. Single- and multiple-dose pharmacokinetics of caspofungin in healthy men. Antimicrob. Agents Chemother. 46 (3), 739-745 (2002).
119. Alffenaar JW, Wessels AM, van Hateren K, Greijdanus B, Kosterink JG, Uges DR. Method for therapeutic drug monitoring of azole antifungal drugs in human serum using LC/MS/MS. J. Chromatogr. B. Analyt Technol. Biomed. Life Sci. 878 (1), 39-44 (2010).
120. van der Elst KC, Span LF, van Hateren K et al. Dried blood spot analysis suitable for therapeutic drug monitoring of voriconazole, fluconazole, and posaconazole. Antimicrob. Agents Chemother. 57 (10), 4999-5004 (2013).
121. Kim HJ, Seo KA, Kim HM et al. Simple and accurate quantitative analysis of 20 anti-tuberculosis drugs in human plasma using liquid chromatography-electrospray ionizationtandem mass spectrometry. J. Pharm. Biomed. Anal. 102, 9-16 (2014).
122. Timmerman P, White S, Globig S, Ludtke S, Brunet L, Smeraglia J. EBF recommendation on the validation of bioanalytical methods for dried blood spots. Bioanalysis 3 (14), 1567-1575 (2011).
123. Wilhelm AJ, den Burger JC, Swart EL. Therapeutic drug monitoring by dried blood spot: progress to date and future directions. Clin. Pharmacokinet. 53 (11), 961-973 (2014).